Meeting
2024 ASCO Genitourinary Cancers Symposium
Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study.
Authors
Xiao Yang
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Xiao Yang , Juntao Zhuang , Qiang Cao , Lingkai Cai , Qikai Wu , Qiang Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04570410
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 619)
DOI
10.1200/JCO.2024.42.4_suppl.619
Abstract #
619
Poster Bd #
H4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.
First Author: Tianxin Lin
Poster
2022 ASCO Annual Meeting
Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC.
First Author: Tianxin Lin
Poster
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
First Author: Qiu-Yan Chen
Poster
2022 ASCO Annual Meeting
Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.
First Author: Nieves Martinez Chanza